LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 34; pp. S1313 - S1314
Main Authors Le, X., Patel, J., Shum, E., Sanborn, R.E., Baik, C.S., Shu, C.A., Kim, C., Fidler, M.D., Hall, R., Hanna, N., Mohindra, N., Sabari, J.K., Heeke, S., Hernandez, M., Gray, J.E., Heymach, J.V., Saltos, A.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.10.2023
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2023.10.072